射血分数保留的心力衰竭研究新进展

New progress in the study of heart failure with preserved ejection fraction

射血分数保留的心力衰竭(HFpEF)患者通常有多种合并症,包括高血压、糖尿病、肥胖等。随着人口老龄化,其在心力衰竭(心衰)中所占比例正逐年升高。由于治疗缺乏循证医学证据支持以及HFpEF功能和结构受损的多样性,与射血分数降低的心力衰竭(HFrEF)相比,HFpEF的非心血管死亡发生率相对较高。因此,寻找HFpEF新的治疗方法已成为当前心衰研究领域的热点。近年来,一些研究取得了新的进展,本文就HFpEF的病理生理机制、诊断、最新药物治疗作一综述。

Patients with heart failure with preserved ejection fraction(HFpEF)usually have a variety of comorbidities,including hypertension,diabetes,and obesity.With the aging of the population,the proportion of HFpEF in the whole heart failure patients is increasing year by year.Due to the lack of evidence-based medical therapy support and the diversity of HFpEF’s functional and structural impairments,the incidence of non-cardiovascular death in HFpEF is relatively higher than that of heart failure with reduced ejection fraction(HFrEF).Therefore,finding new treatments for HFpEF has become a hot spot in the current heart failure research field.In recent years,several studies have achieved new progress.This review summarized the pathophysiological mechanism,diagnosis,and latest drug therapies of HFpEF.